Fig. 5. Anti-inflammatory activity of ^-941. Dose-dependent inhibition of cutaneous irritation in humans by ^-941.
well as psoriasic patients have been obtained. Despite the small number of patients per dose, these data showed a significant trend in favor of a dose/response effect on the patients' clinical benefit, body weight loss, and analgesic consumption (p < 0.01) and allowed scientists to determine the most effective dose to be administered in phase III clinical trials, planned for early 1999.
Was this article helpful?